Special Issue "Clinical and Molecular Diagnosis of Hematologic Malignancies"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 10 June 2023 | Viewed by 2331
Special Issue Editor

Interests: mechanism studies; translational studies; clinical studies of hematolymphoid tumors including multiple myeloma, lymphoma, and leukemia.
Special Issue Information
Dear Colleagues,
In recent decades, rapid progress in biotechnology and the increasing application of multi-omics studies has largely deepened our knowledge of biological features of hematolymphoid neoplasms. As this great amount of new evidence has been translated into high-throughput molecular diagnostic tools, the diagnostic pattern of hematological malignancies has been profoundly re-shaped, with a deliberate attempt made to prioritize classifying tumor types based on defining genetic abnormalities according to the latest 2022 WHO classification of hematolymphoid tumors. Meanwhile, personalized, targeted treatment based on molecular diagnosis has greatly improved the outcomes of patients with hematolymphoid tumors. In the era of precision medicine, embedding novel molecular findings and multi-omics notions into clinical management is the new goal. This Special Issue aims at providing new insights about the updates in the molecular diagnosis and clinical management of hematolymphoid tumors.
Prof. Dr. Peng Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematolymphoid tumors
- genetic alterations
- lymphoma
- leukemia
- myeloma
- precision medicine